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Background: Lipoprotein lipase (LPL) clears triglycerides from the blood, and angiopoietin-like protein 4 (ANGPTL4)
inhibits LPL activity.
Results: Inhibited LPL is in a complex with ANGPTL4, and upon dissociation LPL regains activity.
Conclusion: ANGPTL4 is a reversible, noncompetitive inhibitor of LPL, not an unfolding molecular chaperone as reported
previously.
Significance: Understanding the mechanism of LPL inhibition supports efforts to develop new therapies for
hypertriglyceridemia.
Elevated triglycerides are associated with an increased risk of
cardiovascular disease, and lipoprotein lipase (LPL) is the rate-
limiting enzyme for the hydrolysis of triglycerides from circu-
lating lipoproteins. TheN-terminal domain of angiopoietin-like
protein 4 (ANGPTL4) inhibits LPL activity. ANGPTL4 was pre-
viously described as an unfolding molecular chaperone of LPL
that catalytically converts activeLPLdimers into inactivemono-
mers. Our studies show that ANGPTL4 is more accurately
described as a reversible, noncompetitive inhibitor of LPL. We
find that inhibited LPL is in a complex with ANGPTL4, and
upon dissociation, LPL regains lipase activity. Furthermore, we
have generated a variant of ANGPTL4 that is dependent on
divalent cations for its ability to inhibit LPL. We show that LPL
inactivation by this regulatable variant of ANGPTL4 is fully
reversible after treatment with a chelator.
LPL2 is the key enzyme involved in regulation of serum lipid
levels. LPL is a secreted enzyme that functions on the surface of
the capillary endothelium where it hydrolyzes triglycerides
containedwithin circulating chylomicrons and very lowdensity
lipoprotein to provide free fatty acids to tissues (1). Familial LPL
deficiency is a rare but serious condition that results in
extremely high serum triglyceride levels (severe hypertriglyc-
eridemia) that lead to eruptive xanthomas, lipemia retinalis,
and pancreatitis, resulting in a poor health-related quality of life
and early mortality (2). Mildly elevated serum triglycerides are
more common, with over one-third of Americans suffering
from some level of hypertriglyceridemia (3). Hypertriglyceri-
demia is associated with increased risk of cardiovascular dis-
ease (4) along with predicting the development of type 2 diabe-
tes mellitus (5). Current research is focused on finding ways to
maintain or increase LPL activity to alleviate the effects of
hypertriglyceridemia (6, 7).
LPL belongs to a superfamily of lipases that includes the
mammalian endothelial, pancreatic, and hepatic lipases (8).
There is no crystal structure for LPL, but due to high sequence
similarity with pancreatic lipase, its crystal structure can serve
as amodel to provide information about the structure-function
relationships that govern LPL activity (9, 10). The LPL protein
is composed of two structurally distinct domains that are con-
nected by a short linker. The N-terminal domain includes the
active site, and homology modeling suggests that it takes on an
/-hydrolase fold (9). The C-terminal domain is modeled as a
-sandwich and is responsible for binding the cell surface pro-
tein glycosylphosphatidylinositol-anchored high density lipo-
protein-binding protein 1 (GPIHBP1) (9–11). LPL is only active
as a homodimer, and the two subunits are oriented in a head to
tail fashion such that theN-terminal domain of one LPLmono-
mer faces the C-terminal domain of the other (12, 13).
Because of its key role in regulating lipid homeostasis, LPL
activitymust be tightly coordinatedwith nutritional status. LPL
regulation is tissue-specific such that upon fasting LPL activity
decreases in adipose tissue and increases in muscle tissue (14).
Tissue-specific regulation of LPL is thus thought to direct fatty
acids to adipose tissue for storage when lipids are plentiful and
to muscle tissues for fuel when lipids are scarce. ANGPTL4 is a
secreted protein that directly regulates LPL activity (15). Mice
lacking ANGPTL4 show increased LPL activity and decreased
plasma triglycerides, whereas mice overexpressing ANGPTL4
display elevated plasma triglycerides and reduced LPL activity
(16). ANGPTL4 inhibition of LPL activity is nutritionally
responsive and tissue-specific, as ANGPTL4 expression is
induced in adipose tissue in response to fasting (15, 17).
ANGPTL4 is a two domain protein, and each domain has
been shown to have a distinct biological function. The N-ter-
minal domain is a coiled-coil that mediates oligomerization of
the protein, and the C-terminal portion is a fibrinogen-like
domain (18). After ANGPTL4 is secreted, these domains are
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cleaved apart by the action of pro-protein convertases (18, 19).
The N-terminal domain inhibits LPL activity, and cleavage of
the two domains enhances this inhibition (18, 20, 21). A mech-
anism for LPL inhibition was described, in which ANGPTL4
was termed an unfolding molecular chaperone of LPL (22). In
that study, it was reported that ANGPTL4 inhibits LPL activity
by promoting a conformational change in LPL such that active
LPLdimers dissociate and form inactivemonomers (22). Active
LPL dimers are known to undergo both reversible dissociation
that results in rapid exchange of subunits and irreversible dis-
sociation that results in inactive monomers (12, 23). Irreversi-
ble dissociation can be induced by heat or denaturant and
results in loss of catalytic activity and a change in secondary
structure (23). TheANGPTL4-induced conformational change
in LPL was reported to be akin to irreversible dissociation (22).
We set out to uncover the mechanism by which this confor-
mational change occurs and found instead that ANGPTL4
inhibits LPLby a reversible, noncompetitivemechanism. Inhib-
ited LPL was found in a complex with ANGPTL4, and super-
stoichiometric ratios ofANGPTL4/LPLwere required for com-
plete inhibition. These findings may have considerable in vivo
significance in light of recent data showing that, in humans,
serumANGPTL4 levels do not correlate with plasma triglyceride
levels and that LPL travels bidirectionally across endothelial cells
(24, 25). These data have led to the suggestion that ANGPTL4
could inhibit LPL in the subendothelial space rather than on the
endothelial surface (25). Here, we report our data showing a
noncompetitive mechanism for ANGPTL4 inhibition of LPL
and discuss its possible physiological implications.
EXPERIMENTAL PROCEDURES
Protein Purification, LPL—Bovine LPL was purified from
fresh cow’s milk as described and stored at 80 °C (26).
ANGPTL4—Amino acids 26–161 of ANGPTL4 (the N-ter-
minal coiled-coil domain) were cloned into pET16b (Novagen)
with anN-terminal His tag followed by aGST tag and a tobacco
etch virus cleavage site. Protein was expressed in BL21 (DE3)
cells, and cells were grown to an A600 of 0.5 at 37 °C and then
induced with 0.1 mM isopropyl 1-thio--D-galactopyranoside
for 16 h at 18 °C. Cells were pelleted at 4000  g, suspended in
buffer A (20 mM Tris, pH 7.5, 500 mM NaCl, 40 mM imidazole)
with 1 Complete EDTA-free protease inhibitors (Roche
Applied Science), and lysed in a Nano DeBEE Laboratory
homogenizer (BEE International) at 20,000 p.s.i. The lysate was
cleared at 34,000  g for 20 min and applied to a nickel-nitrilo-
triacetic acid resin (Qiagen) that had been pre-equilibrated
with buffer A. Resin was washed with 10 column volumes of
buffer B (20 mM Tris, pH 7.5, 500 mM NaCl, 80 mM imidazole)
and 10 columnvolumes of bufferC (20mMTris, pH7.5, 150mM
NaCl, 80 mM imidazole). Protein was eluted with buffer C con-
taining an additional 200 mM imidazole. DTT was added to
pooled eluate fractions to a final concentration of 5 mM, and
tobacco etch virus protease was added to 32g/ml to cleave the
N-terminal tags. Protein fractions were dialyzed into Mono S
start buffer (20 mM Tris, pH 7.5, 100 mMNaCl), injected onto a
1-ml Mono S 5/50 GL column (GE Healthcare) pre-equili-
brated with start buffer, and eluted over 20 column volumes
using a linear gradient to start buffer containing 2MNaCl. Frac-
tions containing ANGPTL4were pooled and buffer-exchanged
into HisTrap start buffer (20mMTris, pH 7.5, 300mMNaCl, 40
mM imidazole), injected into a 1-ml HisTrap HP column (GE
Healthcare), and eluted with an imidazole gradient (40–500
mM) in HisTrap buffer over 30 column volumes. Fractions con-
taining clean ANGPTL4 were pooled and buffer-exchanged
into storage buffer (20 mM Tris, pH 7.5, 300 mM NaCl) and
stored at 80 °C. Purified ANGPTL4 was a mixture of mono-
mers and disulfide-bonded dimers and tetramers.
MID1-ANGPTL4—The two cysteine residues of ANGPTL4
(Cys-76 and Cys-80) were mutated to serine residues using
site-directed mutagenesis. Previous studies have shown that
ANGPTL4 (C76S/C80S) inhibits LPL with the same potency
asWT-ANGPTL4 (27), which we confirmed independently (data
not shown). Oligonucleotides designed to encode amino acids
comprising the MID1 tag (28) (SPLAQQIKNIHSFIHQA-
KAAGRMDEVRTLQENLHQLMHEYFQ) were added to the
5 end of the coding sequence for ANGPTL4(26–161) by
overlap extension PCR, creating an N-terminal MID1-tagged
ANGPTL4 construct. The MID1-ANGPTL4 construct was
cloned into pET41a (Novagen) at the NdeI and XhoI sites. Pro-
tein was expressed and purified as stated above using a nickel-
nitrilotriacetic acid column but eluted in buffer B containing an
additional 300 mM imidazole. Fractions containing clean
MID1-ANGPTL4 were pooled, and EDTA was added to a final
concentration of 0.5 mM and incubated at 4 °C for 16 h. Protein
was concentrated using a Centricon concentrator (Amicon)
and further purified using a HiLoad 16/200 Superdex 200 col-
umn (GE Healthcare) pre-equilibrated with storage buffer (20
mMTris, pH 7.5, 300mMNaCl). PurifiedMID1-ANGPTL4was
stored at 80 °C.
Heparin Chromatography—0.5 nmol (100 nM) of bovine LPL
was incubated on ice, at 37 °C, or with 2.4 MANGPTL4 for 20
min in heparin buffer (10 mM BisTris, pH 6.5, 10% glycerol, 0.5
M NaCl). A control reaction, containing only ANGPTL4, was
also incubated on ice for 20 min. After 20 min, column loads
were assayed for LPL activity and then immediately injected
onto a 1-ml HiTrap heparin HP column (GE Healthcare) that
was pre-equilibrated with heparin buffer. After a 10-ml wash
with heparin buffer, 1-ml fractions were eluted from the col-
umn by a linear salt gradient over 30ml from 0.5 to 2 MNaCl in
heparin buffer. Fractions were assayed for lipase activity and
analyzed by Western blot.
LPL Activity Assay—Lipase activity was measured using a
SpectraMax M5 microplate reader (Molecular Devices) and
black-walled, clear-bottom, 96-well plates (Corning Glass).
Assays were conducted in a total of 100 l containing 5 nM
LPL in assay buffer (20 mM Tris, pH 8.0, 150 mM NaCl, 0.2%
fatty-acid free BSA, 0.01% Anzergent 3-16) and 10 M of the
fluorescent substrate 1,2-di-O-lauryl-rac-glycero-3-(glutaric
acid 6-methylresofurin ester) (Sigma). Substrate hydrolysis was
measured as the initial increase in fluorescence over 60 s using
an excitation wavelength of 529 nm, and reading emission at
600 nm with a 590-nm cutoff filter. Assays were conducted at
25 °C and measured in triplicate. In each assay, initial LPL
activity was blanked by subtracting a buffer control (contain-
ing 1,2-di-O-lauryl-rac-glycero-3-(glutaric acid 6-methylreso-
furin ester) without LPL) and was normalized by dividing the
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initial rateof inhibitedLPLactivityby the initial rateofuninhibited
LPL activity. In this way we corrected for the spontaneous loss of
LPL lipase activity. Activity assays for the measurement of Ki
were assayed as above but with 1mMdeoxycholate added to the
assay buffer and between 0.16 and 20 M substrate.
LPL Inhibition Reactions—The LPL inhibition with the
ANGPTL4 time course experiment was conductedwith 100 nM
LPL and between 0 and 1.6 M ANGPTL4 in buffer containing
20 mM Tris, pH 7.5, 300 mM NaCl, 1 mM deoxycholate. Reac-
tions were incubated on ice for up to 6 h. Aliquots of the inhi-
bition reactions were assayed for lipase activity as above. LPL
inhibition with MID1-ANGPTL4 was conducted with 100 nM
LPL and 3.2 M MID1-ANGPTL4 in 20 mM Tris, pH 7.5, 300
mMNaCl, 5mMdeoxycholate, and 30Mnickel sulfate at 37 °C.
After 45 min, aliquots were tested for lipase activity, and then
EDTAwas added to a final concentration of 1mM to chelate the
nickel ions. After 15minwith EDTA, aliquots were again tested
for lipase activity. Inhibition reactions used for the determina-
tion ofKiwere conducted at room temperature with 12 nM LPL
and between 0 and 38.9 M ANGPTL4 in 20 mM Tris, pH 7.5,
300 mM NaCl, and 1 mM deoxycholate. Inhibition reactions
were incubated for 10 min and then diluted into assay buffer as
described above to a final concentration of 5 nM LPL and
between 0 and 16.2 M ANGPTL4.
Thermal Inactivation and Thermofluor Assay—100 nM LPL
was incubated in 10 mM BisTris, pH 6.5, 500 mM NaCl, 10%
glycerolwith orwithout 1mMdeoxycholate at 4, 25, or 37 °C.At
0, 15, 30, and 60 min, aliquots of the LPL reaction were diluted
20 into assay buffer, and initial rates of fluorescent substrate
hydrolysis were measured as above. For the thermofluor assay
(29), 20 l of 900 nM LPL was incubated in 10 mM BisTris, pH
6.5, 500 mM NaCl, and 10% glycerol with 6 SYPRO Orange
(Sigma). Assays were conducted in quadruplicate in a 384-well
real time PCR plate covered with optically clear sealing film.
The plate was incubated at 37 °C in a 7900HT Fast Real Time
PCR machine (Applied Biosystems) for 2 h taking fluorescent
measurements every 7 s.
Western Blots—Heparin chromatography eluate fractions or
LPL/ANGPTL4 cross-linking reactions were separated
using SDS-PAGE (12%), transferred to PVDF, blocked with
5% milk in TBS-T, incubated with anti-ANGPTL4 (BioVen-
dor RD181073100-01) at 1:5000 in 2.5% milk/TBS-T or anti-
LPL (Santa Cruz Biotechnology sc-32885) at 1:1000 in 2.5%
milk/TBST. Blotswerewashed, incubatedwith anti-rabbitHRP
secondary antibody at 1:20,000 in 2.5% milk/TBST, washed,
and exposed to ECL substrate (ADVANSTA Western Bright,
BioExpress), and proteins were detected with autoradiography
film.
Calculation of Ki—The rate of substrate hydrolysis, recorded
as relative fluorescence units/s, was plotted as a function of
substrate concentration. Data were fitted to the rate equation
for noncompetitive inhibition: v  Vmax[S]/{(Km(1  [I]/Ki)) 
([S](1  [I]/Ki))}, where Vmax is the un-inhibited maximum
rate of substrate hydrolysis; Km is the Michaelis-Menten con-
stant; [S] is substrate concentration; [I] is inhibitor concentra-
tion, and Ki is the inhibition constant. Data were fitted using
simultaneous nonlinear regression using Mathematica (Wol-
fram Research).
Glutaraldehyde Cross-linking—Bovine LPL and ANGPTL4
purified as above were buffer-exchanged into 20 mM HEPES,
pH 8.0, 150mMNaCl, 10% glycerol, 1mM deoxycholate, and 1%
Tween 20. 250 nM LPL was incubated between 0 and 5 M
ANGPTL4, or 100 nMANGPTL4was incubatedwith between 0
and 500 nM LPL for 10 min at room temperature. Glutaralde-
hyde was added to a final concentration of 0.25%, and the reac-
tion was incubated at room temperature for 10 min. Cross-
linking reactions were stopped with Tris, pH 8.0, to a final
concentration of 150 mM and analyzed by Western blot as
above.
Atomic Force Microscopy—100 nM LPL, 100 nM ANGPTL4,
or 100 nMLPLplus 100 nMANGPTL4were incubated on ice for
15 min in 10 mM BisTris, pH 6.5, 500 nM NaCl, and 10% glyc-
erol. Mixtures were diluted 5 into the same buffer, and 10 l
was immediately deposited onto freshly cleavedmica. Themica
surface was then immediately washed with water, and a stream
of nitrogen gas was used to dry the surface. Images were
acquired with a Nanoscope III 3A atomic force microscope
(Veeco, Santa Barbara, CA) in tapping mode with a resolution
of 512 512 pixels at a scan rate of 1.97Hz and over a 1 1m
scan size. AFM tips were from NanoSensors (Neuchatel, Swit-
zerland) with a spring constant between 21 and 98 N/m and
resonance frequencies between 146 and 236 kHz. AFM images
for each sample were consistent over multiple depositions
(greater than three from each sample) andmultiple tips (at least
two for each deposition). Poor images resulting from blunted
tips were excluded from analysis. Between three and five repre-
sentative images of each sample condition were 3rd order
plane-fitted and flattened using NanoScope Analysis version
1.40r1 (Bruker Instruments). Volume analysis of protein peaks
was conductedwith Image SXM194-2X (Steve Barrett, Univer-
sity of Liverpool, UK) as described (30). Proteinmolecularmass
was converted into predicted AFM volume using the following
equation: V  1.2M  14.7, where V is AFM volume in nm3,
andM is molecular mass in kDa (31).
RESULTS
ANGPTL4 Is Not a Catalytic Inhibitor of LPL—The previ-
ously published model of LPL inhibition states that sub-stoi-
chiometric quantities of ANGPTL4 to LPL are sufficient to
completely inhibit LPL, and therefore, ANGPTL4 is a catalytic
inhibitor of LPL (22). Our experiments, however, are not con-
sistent with these results and reveal that super-stoichiometric
ratios of ANGPTL4/LPL were needed for complete LPL inhibi-
tion. As is standard for LPL inhibition studies, the N-terminal
coiled-coil domain of ANGPTL4 was used throughout this
study, and we refer to it simply as ANGPTL4. In these experi-
ments, a set amount of LPL was incubated on ice with varying
amounts of ANGPTL4. Aliquots were removed at several time
points over a 6-h period, and the lipase activity of LPL was
measured (Fig. 1A). LPLwithout ANGPTL4was also incubated
on ice and used as the uninhibited control. Fig. 1A shows the
fraction of control activity at the specified time points. Unin-
hibited LPL lost a total of 35% of its starting activity over the 6-h
period. ANGPTL4 inhibited LPL in a dose-dependent manner
within the first 15 min of the experiment. If ANGPTL4 is a
catalytic inhibitor of LPL, we would expect an exponential
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decay of LPL activity over time at sub-stoichiometric ratios of
ANGPTL4 to LPL. However, we observed no additional LPL
inhibition byANGPTL4 after the first time point. Furthermore,
an excess of ANGPTL4 monomers to LPL dimers was needed
to see significant inhibition of lipase activity. These results indi-
cate that ANGPTL4 is not a catalytic inhibitor of LPL.
Heat-inactivated LPL and ANGPTL4-inactivated LPL Are
Not Equivalent—Temperature plays a key role in the stability of
LPL in vitro. Even in the absence of ANGPTL4, LPL is rapidly
inactivated at 37 °C unless accompanied by stabilizing factors
such as deoxycholate (32). Fig. 1B shows a time course of LPL
inactivation at several temperatures. As expected, deoxycholate
(1 mM) stabilizes LPL against thermal inactivation as shown in
Fig. 1C. LPL can be further protected at 37 °C by adding up to 5
mM deoxycholate to the LPL buffer (32). We also show the
effects of heat on LPL inactivation with a fluorescence-based
thermal stability assay (Thermofluor assay) (29, 33). In this
assay, a hydrophobic fluoroprobe is quenched in solution, but
fluorescence emission increases as the probe preferentially
binds to the hydrophobic interior of an unfolded protein. We
incubated LPL with the fluoroprobe at 37 °C for 2 h. Fluores-
cence steadily increased over time and reached a maximum
after 30 min (Fig. 1D), which corresponds to the nearly com-
plete loss of lipase activity after 30 min seen in Fig. 1B. Taken
together, these results indicate that although ANGPTL4 does
not catalytically inactivate LPL, exposure to elevated tempera-
tures results in rapid loss of LPL activity.
Active LPL dimers can be differentiated from inactive LPL
monomers by their different binding affinities to heparin-Sep-
harose resin (34). Previously, it was suggested that heat-inacti-
vated LPL binds heparin with the same affinity as ANGPTL4-
inactivated LPL (22). It was also reported that ANGPTL4 binds
heparin but with a lower affinity than either inactivated LPL or
active LPL dimers (22). In an attempt to understand the mech-
anism of ANGPTL4 inactivation of LPL, we sought to purify
ANGPTL4-inactivated LPL by heparin-Sepharose chroma-
tography. However, in our experiments, we saw that heat-
inactivated LPL bound with a distinctly lower affinity than
ANGPTL4-inactivated LPL (Fig. 2).
Active LPL, heat-inactivated LPL, ANGPTL4-inactivated
LPL, andANGPTL4were found to have distinct elution profiles
on heparin-Sepharose chromatography. LPL samples were
incubated on ice for 20 min, partially heat-inactivated at 37 °C
for 20 min, or incubated with excess ANGPTL4 for 20 min.
Samples were then assayed for lipase activity and separated
using a salt gradient on a heparin-Sepharose column. The con-
tents of the resulting fractions were analyzed by Western blot
and lipase activity assays. First, the positions of active LPL and
partially heat-inactivated LPL were established. Active LPL
dimers eluted from the heparin column at 1.36 M NaCl (Fig.
2A). Partially heat-inactivated LPL eluted from the column in
two distinct peaks as follows: a peak of inactive LPL monomers
at0.85 MNaCl and a peak of active LPL dimers at 1.36 MNaCl
(Fig. 2B). Next, we analyzed LPL that had been partially inacti-
FIGURE 1. Time course of LPL inhibition by ANGPTL4 and LPL inactivation by heat. A, LPL (100 nM) was incubated on ice with ratios of ANGPTL4/LPL ranging
from 0 to 16 ANGPTL4 monomers to 1 LPL dimer in buffer containing deoxycholate. Aliquots of the inhibition reactions were diluted 20 times into assay buffer,
and the fraction of remaining LPL activity was assayed at several time points up to 6 h. For each time point, the inhibited reactions were normalized to the
reaction without ANGPTL4. B, initial LPL activity was measured after incubation for various times at 4, 25, or 37 °C. C, deoxycholate stabilizes LPL as in B, except
that 1 mM deoxycholate was added to the buffer. D, hydrophobic portions of LPL are exposed over time at 37 °C as shown by a fluorescence increase in a
thermofluor assay. RFU, relative fluorescence units; AU, arbitrary units.
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vated by ANGPTL4 (Fig. 2C). Three distinct populations of
proteins eluted from the column. First, a peak containing only
ANGPTL4 eluted from the columnat 0.78MNaCl.Next, a set of
peaks containing both LPL and ANGPTL4 eluted around 1.15
M NaCl, possibly showing multiple LPL-ANGPTL4 complexes.
Finally, a peak containing only active LPL eluted at 1.36 MNaCl.
ANGPTL4 alone was run as a reference (Fig. 2D), confirming
that ANGPTL4 binds to heparin and elutes at 0.78 M NaCl.
These results show that ANGPTL4-inactivated LPL has a
higher affinity for heparin-Sepharose than that of heat-inacti-
vated LPL. In addition, ANGPTL4 remains bound to LPL in one
or more catalytically inactive complexes that co-elute from a
heparin-Sepharose column.
ANGPTL4-inactivated LPL Regains Activity after Heparin
Chromatography—Protein mixtures were assayed for lipase
activity before application to the heparin column, and eluate
fractions were assayed after exiting the column. Fractions with
elution volumes between 28 and 36 ml were the only fractions
showing lipase activity (Fig. 3A). These fractions correspond to
the active LPL peak eluting at 1.36 MNaCl. To directly compare
the activity of LPL eluting off the column, we took the sum
of the lipase activity of each fraction between 28 and 36 ml and
normalized the total activity to the reference run with LPL
incubated on ice. As shown in Fig. 3B, the partially heat-inacti-
vated LPL entered the heparin column with 30% of the lipase
activity as that of the reference LPL. In Fig. 3C, the total LPL
activity exiting the column from the partially heat-inactivated
LPL remained constant at 30% of the reference LPL activity.
LPL that had been partially inactivatedwith ANGPTL4 showed
15% of the reference lipase activity before entering the col-
umn. However, the total lipase activity exiting the column
reached 70% of the reference LPL activity. This result indi-
cates that a portion of the LPL had dissociated fromANGPTL4
and recovered activity upon purification on a heparin column.
ANGPTL4 Inhibition of LPL Is Reversible—The recovery of
LPL activity after heparin chromatography indicates that
FIGURE 2. Separation of active LPL, inactive LPL, and ANGPTL4 using heparin-Sepharose chromatography. Equal amounts of active LPL (0.5 nmol),
heat-inactivated LPL (0.5 nmol for 20 min at 37 °C), ANGPTL4-inactivated LPL (0.5 nmol of LPL with 12 nmol of ANGPTL4), or ANGPTL4 alone (12 nmol) were
separated using a salt gradient using heparin-Sepharose chromatography. Western blots (shown below each trace) against LPL and/or ANGPTL4 were used to
detect the specific protein present in each fraction. A, active LPL elutes late in the salt gradient. B, partial heat-inactivated LPL (20 min at 37 °C) elutes in two
peaks. C, ANGPTL4 inactivation of LPL yields additional peaks that contain both LPL and ANGPTL4. D, ANGPTL4 alone elutes slightly before the heat-inactivated
LPL peak.
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ANGPTL4 inhibition of LPL is a reversible process rather than an
irreversible unfolding reaction (22). This outcome was con-
firmed when we serendipitously generated a regulatable ver-
sion of ANGPTL4 that is active in the presence of nickel ions
and inactive in their absence. Metal-interface-design 1 (MID1)
is a 5-kDa helical protein that forms homodimers mediated by
metal ions (28). Working with N-terminally MID1-tagged
ANGPTL4 (MID1-ANGPTL4), we noticed that, in the absence
of a metal ion, MID1-ANGPTL4 had a reduced ability to
inhibit LPL (Fig. 4A). Upon addition of nickel sulfate, MID1-
ANGPTL4 was an equivalent inhibitor of LPL as compared with
WT ANGPTL4. We also observed that addition of a chelator
(EDTA) to nickel-containing MID1-ANGPTL4 hindered LPL
inhibition back to the level of the apo-form.
We set out to exploit this property of MID1-ANGPTL4 to
determine whether, through the addition and removal of nickel
ions, we could inactivate or reactivate LPL at will. LPL inhibi-
tion reactions were set up according to the schematic in Fig. 4B.
First, WT-ANGPTL4 or MID1-ANGPTL4, pre-mixed with
nickel sulfate, was combined with LPL. LPL alone with nickel-
containing ANGPTL4 buffer served as a positive control. At 45
min, an aliquot of each LPL mixture was assayed for lipase
activity. Each mixture was then split in half, one-half receiving
an excess of EDTA over nickel, and one-half receiving an equal
volume of water. After 15min, eachmixture was assayed again.
Before the addition of EDTA, bothWT- andMID1-ANGPTL4
inhibited LPL to 40% of the control activity (Fig. 4C). Addi-
tion of EDTA to the reaction mixtures had no effect on the
lipase activity of the positive control or on WT-ANGPTL4’s
ability to inhibit LPL. However, EDTA did interrupt MID1-
ANGPTL4 inhibition as LPL activity was restored to nearly 100%
of the positive control. Using the MID1-tagged ANGPTL4, we
were able to show that LPL inhibition by ANGPTL4 is fully
reversible. Unlike earlier inhibition reactions, these reactions
were carried out at 37 °C in the presence of the LPL-stabilizing
agent deoxycholate (32). With the addition of 5 mM deoxy-
cholate to the inhibition reactions, we were able to preserve
75% of the control lipase activity over 60 min at 37 °C. The
reactions were performed at 37 °C to demonstrate that LPL
inhibition by ANGPTL4 is reversible even at increased temper-
ature and is distinct from thermal inactivation.
Molecular Mechanism of Inhibition—Once the reversibility
of theANGPTL4 inhibition reactionwas established, we set out
to better understand the mechanism of inhibition. Analysis of
Michaelis-Menten curves at different inhibitor concentrations
revealed that theVmax decreased with increasing inhibitor con-
centrations. The Km for each inhibitor concentration varied
slightly (with values of 1.4 0.3M (no inhibitor) and 0.5 0.1
M (0.6M inhibitor), 0.7 0.1M (1.8M inhibitor), 1.3 0.2
M (5.4M inhibitor), and 2.0 0.3M (16.2M inhibitor), but
it did not show a decreasing or increasing trend (Fig. 5). These
results are most consistent with a noncompetitive mechanism
of inhibition (35). Data from each inhibitor concentration were
simultaneously fit to an equation for noncompetitive inhibition
FIGURE 3. LPL activity before and after heparin chromatography. A, com-
parison of lipase activity by fraction in the untreated, heat-inactivated, and
ANGPTL4-inactivated LPL samples. B and C, lipase activity of the heat-inacti-
vated and ANGPTL4-inactivated LPL samples relative to the untreated LPL
sample before (B) and after (C) separation by heparin chromatography. All
active fractions for each sample in A were summed to generate relative activ-
ity in C. RFU, relative fluorescence units.
FIGURE 4. MID1-ANGPTL4 requires nickel to be an effective inhibitor. A,
LPL incubated with WT-ANGPTL4 (WT) or MID1-ANGPTL4 (M1) with or with-
out nickel ions. Initial rate of substrate hydrolysis for each sample was normal-
ized to the sample containing LPL without ANGPTL4 or nickel. B, experimental
scheme. LPL was inhibited for 45 min at 37 °C using WT or MID1-ANGPTL4 in
the presence of 5 mM deoxycholate and Ni2. Samples were assayed for lipase
activity and normalized to the positive control without ANGPTL4. Samples
were then split; one fraction received EDTA, and one received an equal vol-
ume of water. Fractions were incubated for 15 min at 37 °C and were then
assayed for lipase activity and normalized to the positive control (no
ANGPTL4 and with EDTA). C, fraction remaining activity by sample where
M1 is MID1-ANGPTL4.
Reversible Inhibition of Lipoprotein Lipase by ANGPTL4
OCTOBER 4, 2013 • VOLUME 288 • NUMBER 40 JOURNAL OF BIOLOGICAL CHEMISTRY 28529
(v  Vmax[S]/{(Km(1  [I]/Ki))  ([S](1[I]/Ki))} (31)) using
nonlinear regression to yield a Ki of 0.86  0.074 M. To gen-
erate a more complete picture of ANGPTL4-inhibited LPL, we
set out to measure the composition of the inhibited complex.
Composition of the Inhibited Complex—Our data show that
complete inhibition of LPL by ANGPTL4 required multiple
ANGPTL4 monomers per LPL dimer (Fig. 1A), that LPL and
ANGPTL4 co-eluted during column chromatography (Fig. 2),
and that inhibition is reversible (Figs. 3 and 4). These data are in
contrast to the previous model in which ANGPTL4 acts as an
unfolding molecular chaperone to yield inactive LPL mono-
mers from active dimers. These contrastingmodels predict dif-
ferent molecular forms of inhibited LPL. Whereas ANGPTL4
acting catalytically as an unfolding molecular chaperone would
increase LPL monomers and decrease LPL dimers, ANGPTL4
acting as a noncompetitive inhibitor would be expected to pro-
duce some higher molecular weight combination of LPL and
ANGPTL4. We utilized AFM and protein-protein cross-link-
ing to probe the stoichiometry of the inhibited complex.
For cross-linking experiments, LPL was first incubated
with increasing amounts of ANGPTL4, cross-linked with
glutaraldehyde, resolved by SDS-PAGE and detected by
Western blot against LPL. LPL alone migrated mainly as
dimers and monomers (migrating at 50 and 100 kDa, Fig.
6A). When ANGPTL4 was added, a band of a higher molecular
weight appeared. Themolecular weight of this slowlymigrating
band appeared to be 220 kDa, consistent with a complex of
two ANGPTL4 tetramers (60 kDa each) to one LPL dimer.
The LPL antibody did not cross-react with the highest concen-
tration of ANGPTL4 alone. Next, ANGPTL4 was incubated
with increasing concentrations of LPL, and the position of
ANGPTL4 was detected by Western blot (Fig. 6B). The appar-
ent molecular weight of the ANGPTL4-reacting bands also
shifted up such that two higher molecular weight bands were
seen. In these experiments the antibody against ANGPTL4 did
not detect the LPL alone.
We next utilized AFM to determine the distribution of olig-
omeric states of the inhibited LPL-ANGPTL4 complex in the
absence of cross-linking. Volume analysis of AFM images has
been shown to be a powerful tool for determining the oligomer-
ization states of proteins, because the AFM volume depends
linearly on the molecular weight of the protein (30, 31).
ANGPTL4,LPL, andLPL-ANGPTL4were imaged.Table1 shows
the predicted AFM volumes for various LPL and ANGPTL4
protein complexes. Images of ANGPTL4 alone yielded protein
volumes ranging from 5 to 60 nm3, which is consistent with
ANGPTL4 dimers and tetramers (Fig. 7A). ANGPTL4 mono-
mers may also be present, but with a predicted AFM volume of
3 nm3, proteins of this size fall below the linear range of the
AFM volume dependence on molecular weight. LPL alone
showed a broad distribution of volumes between 60 and 110
nm3, likely representing the dimer form (Fig. 7B). Topograph-
ical analysis of the LPL images show tightly spaced protein
peaks, also indicative of dimeric proteins. A minor population
of smaller particles was also seen, and we attribute these to an
LPL cleavage fragment known to co-purify with full-length
LPL. Addition of ANGPTL4 to LPL increased the observed vol-
ume of the protein particles (Fig. 7C). If ANGPTL4 catalytically
transformed LPL dimers into LPLmonomers, we would expect
an increase in particles near the expected monomer volume of
46 nm3. Furthermore, we would expect the distribution of
ANGPTL4 protein volumes to remain between 5 and 60 nm3. If
ANGPTL4 and LPL did not interact at all, we would predict a
combined volume distribution representing theANGPTL4 dis-
tribution added to the LPL distribution. Instead, we see the
volume of the main peak increase to between 110 and 160 nm3.
These AFM volumes could represent LPL dimers in complex
with either ANGPTL4 monomers or ANGPTL4 dimers. They
FIGURE 5. ANGPTL4 inhibition of LPL is noncompetitive. 12 nM LPL was
incubated with between 0 and 16.3 M ANGPTL4 for 10 min at room temper-
ature in the presence of 1 mM deoxycholate. Inhibition reactions were diluted
2.4 into assay buffer, and the initial rate of substrate hydrolysis by LPL was
recorded with increasing amounts of fluorescent substrate. Solid lines repre-
sent the best fit to an equation for noncompetitive inhibition solved simulta-
neously for all ANGPTL4 concentrations. RFU, relative fluorescence units.
FIGURE 6. Cross-linking reveals complexes of LPL and ANGPTL4. A, LPL
was incubated with increasing amounts of ANGPTL4, cross-linked using glu-
teraldehyde, and detected by Western blot using antibody against LPL. B,
ANGPTL4 was incubated with increasing amounts of LPL, cross-linked using
gluteraldehyde, and detected by Western blot using an ANGPTL4 antibody.
Arrows point to the LPL-ANGPTL4 cross-linked complex.
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could also correspond to LPL monomers in complex with
ANGPTL4 tetramers. We believe this last option to be unlikely
as there was a complete loss of the LPL dimer peak seen
between 60 and 110 nm3. With a 1:1 molar ratio of ANGPTL4
monomers to LPL dimers, there would not be sufficient
ANGPTL4 tetramers to complex with each LPL monomer. By
both cross-linking and AFM, we observed an increase in the
molecularweight of LPLupon addition ofANGPTL4.This clearly
indicates that ANGPTL4 does not simply monomerize LPL
dimers but instead forms an LPL-ANGPTL4 complex.
DISCUSSION
Here, we demonstrate that ANGPTL4 is a reversible, non-
competitive inhibitor of LPL. Reversibility is demonstrated in
two ways. First, the ANGPTL4-LPL complex partially dissoci-
ates during affinity chromatography, and active LPL is recov-
ered. Second, we generated MID1-ANGPTL4, a regulatable
variant of ANGPTL4. Use ofMID1-ANGPTL4 showed that the
metal-bound, functional form of MID1-ANGPTL4 inhibited
LPL, but full LPL activity was recovered when MID1-ANGPTL4
was disabled by the addition of a chelator. After reversibility
was demonstrated, inhibition kinetics were measured and
found to be consistent with a noncompetitive mechanism.
Finally, we show by AFM, protein-protein cross-linking, and
column chromatography that the inhibited form of LPL is
bound to ANGPTL4. Significantly, these data are consistent
with a previous in vivo study showing that, in plasma frommice
overexpressing ANGPTL4, ANGPTL4 and LPL form a com-
plex as they co-migrate during heparin-Sepharose chromatog-
raphy (36). Thus, our data show that ANGPTL4 acts as a con-
ventional, noncompetitive inhibitor that binds to LPL and
prevents it from hydrolyzing substrates.
Our data are in contrast to the previously published model
for LPL inhibition by ANGPTL4 (Fig. 8) (22). By the earlier
model, ANGPTL4 catalyzes a conformational switch of the
active, dimeric LPL to an inactive, monomeric LPL. It was thus
described as an unfolding molecular chaperone. However,
unlike many unfolding molecular chaperones (37), ANGPTL4
does not utilize any external energy source such as ATP. The
thermodynamics of this earlier model would require that active
LPL exists in a higher energy form than inactive LPL and that
ANGPTL4, through transient contact, could release this
energy.Wedid see a rapid, irreversible loss of LPL activitywhen
we incubated our inhibition reactions at 37 °C without stabiliz-
ing factors and hypothesize that thermal inactivation could
account for these earlier results. It is well established that, in the
absence of the stabilizing influence of its in vivo interacting
partners, LPL requires additives such as deoxycholate and high
salt to maintain activity during in vitro studies (26, 32, 38). For
TABLE 1
Predicted AFM volumes based on the linear dependency of AFM vol-
ume to protein molecular weight: V  1.2M  14.7, where V is AFM





ANGPTL4 monomer 15 3a
ANGPTL4 dimerb 31 22
ANGPTL4 tetramerb 62 59
LPL monomer 51 46
LPL dimerc 101 107
LPL monomer  ANGPTL4
monomer
66 65
LPL monomer  ANGPTL4
dimer
81 83
LPL monomer  ANGPTL4
tetramerd
112 120
LPL dimer  ANGPTL4
monomerd
117 125
LPL dimer  ANGPTL4
dimerd
132 144
LPL dimer  ANGPTL4
tetramer
163 181
a Out of linear range.
b ANGPTL4 dimers and tetramers are most likely represented in Fig. 7A.
c LPL dimers are seen in Fig. 7B.
d Possible LPL-ANGPTL4 complexes are seen in Fig. 7C.
FIGURE 7. Distribution of AFM particle volumes in cubic nanometers. Par-
ticle distributions normalized by the percent of total particles in each size
range. Topographical images correspond to an 80  80-nm area on the sur-
face and between 0 and 1.5 nm off the surface. A, ANGPTL4 at 20 nM deposited
onto a freshly cleaved mica surface and imaged with tapping mode AFM in
air. Particles from four representative images from the same deposition and
using the same tip were analyzed totaling 2150 particles. B, same as A., but
with 20 nM LPL. Data from five representative images using the same tip
totaling 1726 particles. C, LPL at 100 nM was combined with 100 nM ANGPTL4,
incubated on ice for 15 min, then diluted to a final concentration of 20 nM LPL
and 20 nM ANGPTL4. Samples were immediately deposited onto freshly
cleaved mica and imaged as in A and B. Data from three representative
images using the same tip total 1719 particles.
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this reason, all inhibition reactions done here are either incu-
bated on ice or at 37 °C with deoxycholate to slow the sponta-
neous in vitro LPL inactivation. Furthermore, all inhibition
experiments were corrected for this spontaneous LPL inactiva-
tion by using LPL alone as a control.
Mechanism of Inhibition—Analysis of ANGPTL4 inhibition
kinetics reveals a noncompetitivemechanism. Noncompetitive
inhibition effectively removes a portion of the enzyme from the
reaction. This can occur by allosteric distortion of the active site
upon inhibitor binding, which does not prevent substrate bind-
ing but renders the enzyme catalytically inactive (35). Alterna-
tively, noncompetitive inhibitors can bind at sites other than
the active site but sterically block substrate access (35, 39). Both
models represent possible noncompetitive mechanisms for
inhibition because they do not compete with substrate for the
active site of the enzyme. Sites in LPL for allosteric inhibition by
ANGPTL4 are currently not known. A possible model for inhi-
bition by steric block is that ANGPTL4 could bind to the LPL
lid region and prevent LPL from accessing substrate. Distin-
guishing the precise mechanisms of ANGPTL4 inhibition of
LPL will require further analysis of the LPL-ANGPTL4
interaction.
Physiological Consequences of Reversible ANGPTL4 Inhi-
bition—The precise cellular location where LPL inhibition
occurs is currently unresolved. Although LPL functions on the
apical face of capillary endothelial cells, it is not made by the
endothelial cells but rather the underlying adipocyte or myo-
cyte cells (40). The protein GPIHBP1 binds to the endothelium
of capillary cells where it provides a platform for LPL to process
triglycerides from lipoproteins (41). GPIHBP1 also helps trans-
port LPL across the endothelial cells, and a recent study has
shown that this transport is bidirectional (25, 42). ANGPTL4
could thus inhibit LPL in either the subendothelial space or on
the surface of the capillary endothelium, and a number of recent
studies support the former option. First, although ANGPTL4 is
known to regulate LPL activity in vivo and in vitro, two stud-
ies in human populations found no correlation between
serum ANGPTL4 and triglyceride levels (24, 43). Full-length
ANGPTL4 is known to interact with the extracellular matrix in
the subendothelial space via its C-terminal domain (44). Next,
serum lipoproteins have been shown to prevent inhibition of
LPL by ANGPTL4, and it is estimated that the concentration of
circulating lipoproteins would be sufficient to prevent inhibi-
tion on the apical face of the capillary cells (45). GPIHBP1 also
protects LPL against inhibition by ANGPTL4, and GPIHBP1 is
made by endothelial cells and found both on their apical and
basolateral surfaces (38, 41).
These findings, combined with our model for reversible
inhibition of LPL, evoke the possibility that ANGPTL4 could
sequester LPL in the subendothelial space. By this model,
ANGPTL4 binding to LPL could prevent its movement to the
apical face of endothelial cells. Inhibition could be reversed
and active LPL released when appropriate nutritional cues
emerged.We can only speculate on the nature of these cues, but
certain biological molecules such as free fatty acids reduce
ANGPTL4 inhibition of LPL (46). Because fatty acids aremobi-
lized to the circulation from adipose tissue upon fasting (47),
they are unlikely to be the specific cue that releases ANGPTL4
inhibition of LPL. However, a small molecule capable of revers-
ing ANGPTL4 inhibition of LPL provides an appealing model
for nutritionally responsive LPL regulation.
Although further studies will be required to understand the
significance of reversible LPL inhibition by ANGPTL4 in vivo,
achieving this understanding is important because genetic
studies in humans strongly support a role for ANGPTL4 in
regulation of plasma triglyceride levels. A naturally occurring
sequence variant of ANGPTL4, E40K, is present in 3% of Euro-
pean-Americans. This variant is found to be significantly asso-
ciated with lower plasma triglycerides and higher HDL-C (43,
48), an athero-protective lipid profile. It is thus likely that
ANGPTL4 is a prime pharmacological target for the treatment
of hypertriglyceridemia (6). For example, inhibiting ANGPTL4
with a neutralizing antibody lowered plasma triglyceride levels
in hypertriglyceridemic mice, and such antibodies are sug-
gested to have potential therapeutic applications in dyslipi-
demia (49). For these studies, a more complete understanding
of the activity and availability of the cellular pools of LPL is
necessary.
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